Association of trilaciclib use with hematologic outcomes during perioperative immunochemotherapy in resectable esophageal squamous cell carcinoma: a prospective observational cohort study
Background Perioperative immunochemotherapy is a key treatment strategy for resectable esophageal squamous cell carcinoma (ESCC), but chemotherapy-induced myelosuppression (CIM) may compromise treatment delivery. Trilaciclib, a transiently acting, reversible cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has shown mye...